Harmony Biosciences Holdings Inc Dossier
Qualitative Analysis
Business overview
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological diseases who have unmet medical needs. Headquartered in Plymouth Meeting, Pennsylvania, the company was founded in 2017. Harmony's flagship commercial product is WAKIX (pitolisant), a first-in-class molecule designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX is FDA-approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. The company is actively expanding its clinical pipeline, targeting other rare neurological conditions such as Prader-Willi Syndrome, Myotonic Dystrophy, and Fragile X Syndrome.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Vigorously defending WAKIX intellectual property and developing next-generation formulations (Pitolisant GR and Pitolisant HD) to extend market exclusivity into the 2030s and 2040s.
Expected impact: Mitigates the risk of the WAKIX patent cliff (expected around 2030) and expands the addressable patient population.
Advancing late-stage clinical programs acquired through business development, including EPX-100 for rare epilepsies and ZYN002 (cannabidiol gel) for Fragile X syndrome.
Expected impact: Reduces single-product dependency on WAKIX by establishing revenue streams in new therapeutic areas.
Actively evaluating and executing strategic transactions to acquire or in-license assets with significant revenue potential.
Expected impact: Accelerates the transition to a diversified, multi-product neuroscience leader.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to add EPX-100 (clemizole hydrochloride), a late-stage, potentially disease-modifying drug candidate for rare childhood epilepsies (Dravet syndrome and Lennox-Gastaut syndrome), to Harmony's pipeline.
Financial impact: Increased R&D expenses due to ongoing Phase 3 trials, with potential milestone payments and royalties upon commercialization.
Acquired to obtain Zygel (ZYN002), a pharmaceutically manufactured cannabidiol gel in Phase 3 development for Fragile X syndrome and other orphan neuropsychiatric disorders.
Financial impact: Expanded late-stage pipeline and increased clinical trial operational costs.
Strategic Partnerships
Collaborating on the research and development of discovery-stage candidates CBS105 (for treatment-resistant narcolepsy) and CBS104 (for refractory epilepsy) using cell replacement therapy.
Terms: Harmony obtained an option to license the candidates; specific upfront and milestone payments were not fully disclosed.
Obtained exclusive rights to develop, manufacture, and commercialize BP1.15205 (now BP-205), a potential best-in-class orexin-2 receptor agonist, in the United States and Latin American territories.
Terms: Includes upfront licensing fees, development milestones, and royalties on future net sales.